SI1513519T1 - Uporaba substituiranih cianopirolidinov za zdravljenje hiperlipidemije - Google Patents

Uporaba substituiranih cianopirolidinov za zdravljenje hiperlipidemije

Info

Publication number
SI1513519T1
SI1513519T1 SI200331571T SI200331571T SI1513519T1 SI 1513519 T1 SI1513519 T1 SI 1513519T1 SI 200331571 T SI200331571 T SI 200331571T SI 200331571 T SI200331571 T SI 200331571T SI 1513519 T1 SI1513519 T1 SI 1513519T1
Authority
SI
Slovenia
Prior art keywords
treating hyperlipidemia
substituted
hyperlipidemia
methods
cyanopyrrolidines
Prior art date
Application number
SI200331571T
Other languages
English (en)
Slovenian (sl)
Inventor
David Grenville Holmes
Thomas Edward Hughes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1513519T1 publication Critical patent/SI1513519T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331571T 2002-06-03 2003-06-02 Uporaba substituiranih cianopirolidinov za zdravljenje hiperlipidemije SI1513519T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38522002P 2002-06-03 2002-06-03
EP03737984A EP1513519B1 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines for treating hyperlipidemia
PCT/EP2003/005762 WO2003101448A1 (en) 2002-06-03 2003-06-02 The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases

Publications (1)

Publication Number Publication Date
SI1513519T1 true SI1513519T1 (sl) 2009-06-30

Family

ID=29712145

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331571T SI1513519T1 (sl) 2002-06-03 2003-06-02 Uporaba substituiranih cianopirolidinov za zdravljenje hiperlipidemije

Country Status (25)

Country Link
US (2) US20050176806A1 (https=)
EP (1) EP1513519B1 (https=)
JP (2) JP2005532338A (https=)
KR (1) KR20050012771A (https=)
CN (2) CN100402026C (https=)
AT (1) ATE422884T1 (https=)
AU (2) AU2003245903B2 (https=)
BR (1) BR0311535A (https=)
CA (1) CA2487297C (https=)
CY (1) CY1112800T1 (https=)
DE (1) DE60326232D1 (https=)
DK (1) DK1513519T3 (https=)
EC (1) ECSP045469A (https=)
ES (1) ES2321600T3 (https=)
IL (1) IL165181A (https=)
MX (1) MXPA04012149A (https=)
NO (1) NO333585B1 (https=)
NZ (1) NZ536832A (https=)
PL (1) PL210408B1 (https=)
PT (1) PT1513519E (https=)
RU (1) RU2362555C2 (https=)
SG (1) SG154333A1 (https=)
SI (1) SI1513519T1 (https=)
WO (1) WO2003101448A1 (https=)
ZA (1) ZA200409136B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422884T1 (de) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
RU2766487C2 (ru) * 2004-01-20 2022-03-15 Новартис Аг Композиция и способ прямого прессования
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2114154B1 (en) * 2007-02-08 2013-08-28 Merck Sharp & Dohme Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2795513A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA021236B1 (ru) * 2012-10-03 2015-05-29 Дафот Энтерпраизес Лимитед Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのPPARγアゴニスト
CA3132379A1 (en) * 2019-03-22 2020-10-01 Rush University Medical Center Combination of nasal gene delivery and oral cinnamic acid, oleamide or gemfibrozil for lysosomal storage disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
TW222626B (https=) * 1991-07-22 1994-04-21 Pfizer
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP2583675A1 (en) * 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6468998B1 (en) * 1998-11-02 2002-10-22 Mitsubishi Pharma Corporation Pyrrolidine compounds and medicinal utilization thereof
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
JP4232332B2 (ja) * 1999-11-10 2009-03-04 末藏 岩田 タンク付電動床磨機用ブラシ台
EP1743655B1 (en) * 2000-01-21 2014-06-25 Novartis AG Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
JP2005507261A (ja) * 2001-10-31 2005-03-17 ノバルティス アクチエンゲゼルシャフト Tcf1遺伝子における多型に基づく糖尿病および関連状態の治療方法
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
ATE422884T1 (de) * 2002-06-03 2009-03-15 Novartis Pharma Gmbh Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
EP1928499B1 (en) * 2005-09-20 2011-06-29 Novartis AG Use of a dpp-iv inhibitor to reduce hypoglycemic events

Also Published As

Publication number Publication date
AU2006246483B2 (en) 2010-06-24
ECSP045469A (es) 2005-01-28
EP1513519A1 (en) 2005-03-16
NO20045452L (no) 2005-03-01
PL210408B1 (pl) 2012-01-31
RU2004139029A (ru) 2005-08-27
CY1112800T1 (el) 2016-02-10
CN1658867A (zh) 2005-08-24
ES2321600T3 (es) 2009-06-09
ZA200409136B (en) 2005-07-27
MXPA04012149A (es) 2005-04-19
CA2487297C (en) 2011-08-09
JP2005532338A (ja) 2005-10-27
IL165181A (en) 2010-06-16
DK1513519T3 (da) 2009-06-02
PL374016A1 (en) 2005-09-19
SG154333A1 (en) 2009-08-28
NZ536832A (en) 2006-11-30
AU2006246483B9 (en) 2010-08-12
AU2003245903A1 (en) 2003-12-19
CN101273987A (zh) 2008-10-01
DE60326232D1 (de) 2009-04-02
US20050176806A1 (en) 2005-08-11
ATE422884T1 (de) 2009-03-15
BR0311535A (pt) 2005-02-22
CN100402026C (zh) 2008-07-16
NO333585B1 (no) 2013-07-15
IL165181A0 (en) 2005-12-18
RU2362555C2 (ru) 2009-07-27
HK1074794A1 (en) 2005-11-25
AU2006246483A1 (en) 2006-12-21
JP2010155866A (ja) 2010-07-15
US20120014907A1 (en) 2012-01-19
KR20050012771A (ko) 2005-02-02
PT1513519E (pt) 2009-05-06
CA2487297A1 (en) 2003-12-11
AU2003245903B2 (en) 2006-11-30
EP1513519B1 (en) 2009-02-18
WO2003101448A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
PT1513519E (pt) Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
SI1487444T1 (sl) Uporaba piridil-amidov kot inhibitorjev angiogeneze
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
ATE361287T1 (de) Neue indol-2-on derivate
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
IL152073A0 (en) Percyquinnin, a process for its production and its use as a pharmaceutical
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
YU94103A (sh) Novi derivati sulfonske kiseline
TW200716597A (en) Novel piperidine-substituted indoles
MY143862A (en) Piperidine-substituted indoles-or heteroderivatives thereof
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
DK0706796T3 (da) Dopamingenoptagelsesinhibitorer til behandling af parkinsonisme